Print Page     Close Window     

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
02/03/17Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will participate in two upcoming investor conferences: Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday, February 7, 2017 in New York, NY 6th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 15, ... 
 Printer Friendly Version
01/31/17Seres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses
- Findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patients, contributed to the previously reported SER-109 Phase 2 study outcome - - FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109 - - Conference call at 8 a.m. ET today - CAMBRIDGE, Mass., January 31, 2017 —Seres Therapeutics Inc., (NASDAQ:MCRB), a leading mi... 
 Printer Friendly Version
01/30/17Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Tuesday, January 31, 2017 at 8:00 a.m. ET to discuss the results of its in-depth analyses of the previously reported SER-109 Phase 2 clinical study in patients with multiply recurrent C. difficile infection. To ac... 
 Printer Friendly Version

© Seres Therapeutics. All Rights Reserved.